Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30217843 | 0.84 | ERN1 (0.52) | ERN1HCAR1KDM1ACYP2A6NT5E | |
| SCHEMBL28949295 | 0.84 | ERN1 (0.52) | ERN1HCAR1KDM1ACYP2A6NT5E | |
| SCHEMBL2299449 | 0.80 | KDM1A (0.42) | ERN1HCAR1KDM1ANT5EALDH1A1 | |
| SCHEMBL333114 | 0.78 | IDO1 (0.42) | ERN1HCAR1PTPN1ALDH1A1KIF11 | |
| SCHEMBL6852469 | 0.78 | APP (0.49) | ERN1ALDH1A1KIF11APP | |
| SCHEMBL472401 | 0.78 | CES2 (0.50) | ERN1HCAR1KIF11APP | |
| SCHEMBL10408709 | 0.76 | ALDH1A1 (0.42) | ERN1CYP2A6ALDH1A1KIF11APP | |
| SCHEMBL1781235 | 0.76 | ERN1 (0.52) | ERN1KDM1ACYP2A6NT5EPTPN1 | |
| SCHEMBL502871 | 0.76 | TDP1 (0.55) | ERN1HCAR1PTPN1KIF11APP | |
| SCHEMBL3718412 | 0.76 | APP (0.51) | ERN1ALDH1A1KIF11APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025224085-A1 | COMPOUNDS CAPABLE OF ACTING ON S1R AS WELL AS ON SEH AND USES THEREOF | UNIVERSITAT DE BARCELONA (ES) | 2025-10-30 | — | — | WO | disclosed |
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | ABBVIE INC (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| CN-116410756-B | Liquid crystal compound containing polyfluorofenanthrene structure and application thereof | 北京云基科技股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-12258340-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2025-03-25 | — | — | US | disclosed |
| CN-116473965-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | SUZHOU ARK BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-01-23 | — | — | US | disclosed |
| EP-4480482-A2 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | AbbVie Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | ABBVIE INC. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-115703768-B | Compounds useful as inhibitors of ATR kinase | 苏州爱科百发生物医药技术有限公司 | 2024-12-17 | — | — | CN | disclosed |
| CN-101541747-A | Biphenyl amide lactam derivatives as inhibitors of 11- beta-hydroxysteroid dehydrogenase 1 | LILLY CO ELI (US) | 2009-09-23 | — | — | CN | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-06-18 | — | — | US | disclosed |
| EP-2049481-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SmithKline Beecham Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| EP-2016047-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-23 | — | — | US | disclosed |
| WO-2008092785-A1 | NOVEL 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007124337-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11- BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304568-A1 | PYRIMIDINES FOR DEGRADING BRUTON'S TYROSINE KINASE | BTK, TYMP, LYN | ERN1 223/4885HCAR1 2098/4885KDM1A 568/4885 |
| US-20250026742-A1 | COMPOUND AS ATR KINASE INHIBITOR | ATR, CHEK2, CHEK1 | ERN1 460/4885HCAR1 4570/4885KDM1A 1908/4885 |
| US-12258340-B2 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | ERN1 1174/4885HCAR1 3754/4885KDM1A 2496/4885 |
| US-20250122223-A1 | HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS | USP7, UBA7, SENP7 | ERN1 1151/4885HCAR1 3348/4885KDM1A 303/4885 |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HAVCR2, SARS1, RPL35 | ERN1 487/4885HCAR1 4669/4885KDM1A 3691/4885 |
| US-20090156571-A1 | BIPHENYL AMIDE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD11B2 | ERN1 1347/4885HCAR1 179/4885KDM1A 251/4885 |
| US-20080261920-A1 | 2-Aminooxazolines as TAAR1 ligands | TAAR1, TAAR5, NPY2R | ERN1 3566/4885HCAR1 77/4885KDM1A 2377/4885 |
| US-12172992-B2 | Pyrimidines for degrading Bruton's tyrosine kinase | BTK, TYMP, LYN | ERN1 223/4885HCAR1 2098/4885KDM1A 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.